Navigation Links
Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
Date:12/11/2009

ients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

About Circassia

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed three fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Invesco Perpetual, Goldman Sachs and Lansdowne Partners.

    For more information please visit http://www.circassia.co.uk.

    Contacts
    Steve Harris Rob Budge
    CEO RJB Communications
    Circassia Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241


SOURCE Circassia Ltd


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
2. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
3. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
4. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
5. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
6. Apnex Medical, Inc. Raises Additional $14 Million
7. Cambridge-based Ligon Discovery Raises $1M in Seed Funding
8. FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for Americas Disabled Veterans
9. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
10. NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
11. Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... , July 2, 2015  Konica Minolta, Inc. (Konica ... that it has acquired Sawae Technologica Ltda., an X-ray ... Brazil , through its Brazilian healthcare sales company, ... Local Brazil market ... increasing population exceeding 200 million, significant healthcare technical advancements ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... treated with Satraplatin Demonstrated Statistically,Significant Improvement in ... March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion,Corporation and ... from,the double-blind, randomized satraplatin Phase 3 registrational,trial, ... Cancer) which were presented today at the ...
... Scientists,at WEHI have made a discovery with potentially ... undergoing,cancer chemotherapy. , The research team led by ... platelet life span is controlled by two key,molecules. ... new,drug to prolong the life span of platelets ...
Cached Medicine Technology:Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 2Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 3Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 4Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 5Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 6Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 7Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 2Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 3
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer Institute in ... one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just ... Researchers report that five mesothelioma patients treated with 25Gy of radiation over five days ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... the solar industry’s leading recognition of technical sales expertise from the North American ... Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established national ...
(Date:7/3/2015)... ... 03, 2015 , ... Scientists at several top US cancer centers believe they ... exposure. Click here to read the complete story , just posted on the ... Sinai Medical Center, and New York University exposed mice with a mutation on the ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... says will reveal biblical truth and expose popular lies regarding proper relationships according to ... Have Sex”, immediately goes into the core of the subject by explaining why certain ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... Health researchers have received nearly $13 million from the ... for victims of terrorist attacks, wartime use of toxic ... in these studies will be ,mustard gas, (sulfur mustard) ... is that they are designed to provide rescue treatments," ...
... -- In findings with major implications for the genetics of ... Center (BIDMC) and two other science teams in New York ... networks and showed how it may work to drive cancer ... 14 in the journal Cell describe aspects of ...
... times could cause men to seek more sexual partners, giving ... Gillath, a social psychology professor at the University of Kansas. ... when faced with a threatening environment, according to sexual selection ... think about their own death, which mimics conditions of "low ...
... a five year project with a $2 million ceiling ... the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined ... to prevent the acquisition of HIV and Herpes Simplex ... and acceptable, this combination of products would provide women ...
... (HealthDay News) -- Materialistic couples may have more money, ... a new study. Researchers have found that ... on couples, happiness and stability. In conducting the ... completed by more than 1,700 married couples across the ...
... have new avenues for scientific interaction, following a cooperation ... the government of Singapore. The agreement will allow Singapore ... It also means that EMBO workshops and lectures can ... agreement of its kind between EMBO, EMBC and Singapore. ...
Cached Medicine News:Health News:National Jewish Health researchers awarded $13 million to evaluate treatments for toxic gases 2Health News:Researchers discover hidden genetic influence on cancer 2Health News:Researchers discover hidden genetic influence on cancer 3Health News:Researchers discover hidden genetic influence on cancer 4Health News:Researchers discover hidden genetic influence on cancer 5Health News:Permanently dismal economy could prompt men to seek more sex partners 2Health News:USAID awards cooperative agreement to CONRAD for multipurpose prevention study 2Health News:Couples Can Pay a Price for Materialism 2Health News:Scientists in Singapore and Europe to collaborate 2
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Designated most popular model or size....
Designated most popular model or size. Double-ended. 2 mm wide....
Desmarres Retractor Size 4...
Medicine Products: